Alloantibodies to XXXX in @entity447 .

@entity1 @entity2801 @entity645 @entity447
Up to one-third of @entity447 @entity1 develop @entity2801 ( @entity2801 ) alloantibodies (inhibitors). The Bethesda assay detects inhibitors but is relatively insensitive. Recently, a new fluorescence-based immunoassay (FLI) was developed for antibody detection. The aim of this study was to assess the prevalence of inhibitors as measured by FLI. Assays of @entity2801 , @entity2801 inhibitor by Bethesda assay with Nijmegen modification, and @entity2801 inhibitor by FLI were performed on adult @entity1 with @entity447 . Data were complete for 46 @entity1 (median age 39), of whom 72% were severe, 7% moderate and 22% mild. The Bethesda assay was positive in only two @entity1 (4%), while FLI was positive in 23 of 46 @entity1 (50%), with values ranging from 0.4 to 33.7 nm (median 3.5   nm). FLI titres exceeded 7.0 nm in 19.5% of @entity1 , all but one of whom had severe @entity447 . FLI antibody-positive @entity1 were less likely to be @entity645 positive (30% vs. 70%, P   =   0.02). The use of a prophylaxis regimen was associated with a lower incidence of antibody; only two of 23 @entity1 with detectable antibody and none of those with antibody >7   nm were on a prophylaxis regimen, while nine of 23 patients without antibody were on prophylaxis, (P = 0.03). There was no difference in inhibitor presence in @entity1 using recombinant versus plasma-derived factor. Antibodies detected by FLI are frequent in @entity1 with @entity447 , but are less common in those who are @entity645 positive or are receiving regular @entity2801 prophylaxis.
